Caricamento...
Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
BACKGROUND: The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of...
Salvato in:
| Pubblicato in: | EJNMMI Res |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Berlin Heidelberg
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6365580/ https://ncbi.nlm.nih.gov/pubmed/30725219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-019-0484-y |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|